Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652867 | 0.83 | ALDH1A1 (0.48) | ADORA2BMGLLHCAR1ADORA2AOPRM1 | |
| SCHEMBL7652334 | 0.80 | HCAR1 (0.39) | ADORA2BADORA3MGLLHCAR1ADORA2A | |
| SCHEMBL7654345 | 0.80 | GAA (0.40) | ADORA3MGLLHCAR1KDM4EALDH1A1 | |
| SCHEMBL7650490 | 0.80 | MAPK11 (0.40) | ADORA3MGLLHCAR1KDM4EALDH1A1 | |
| SCHEMBL7657329 | 0.79 | ADORA3 (0.54) | ADORA3MGLLHCAR1ADORA2AKDM4E | |
| SCHEMBL7650664 | 0.77 | ADORA3 (0.44) | ADORA2BADORA3ADORA2AKDM4EALDH1A1 | |
| SCHEMBL16590395 | 0.76 | MGLL (0.44) | ADORA2BADORA3MGLLADORA2AL3MBTL1 | |
| SCHEMBL7649183 | 0.75 | CDK4 (0.43) | ADORA3HCAR1OPRM1ALDH1A1HSD17B10 | |
| SCHEMBL12400717 | 0.74 | ADORA2B (0.48) | ADORA2BADORA3ADORA2AKDM4EALDH1A1 | |
| SCHEMBL7652937 | 0.74 | TNKS (0.47) | ADORA3KDM4EALDH1A1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | claimed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | claimed |
| US-6492407-B2 | NEUROPROTECTIVE ACTIVITY | BOEHRINGER IMGELHEIM PHARMA KG (DE) | 2002-12-10 | — | — | US | disclosed |
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045651-A1 | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | PARK7, IAPP, HIF1AN | ADORA2B 1120/4885ADORA3 1892/4885MGLL 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.